At about 7:00 a.m. on January 1, a 4-year-old child with spinal muscular atrophy (SMA) in Zaozhuang City, Shandong Province, successfully injected the targeted therapeutic drug nocinazone sodium.
The patient's mother said: "This medicine was too far away for us before, but now we finally see hope. ”
Northinalsan sodium injection is the first imported drug approved for the treatment of spinal muscular atrophy in China. When entering the Chinese market in 2019, the price per needle was nearly 700,000 yuan.
In the negotiations on drugs in the national medical insurance catalogue last year, Nocinasson sodium injection was "soul bargaining", entered the medical insurance at a price of 33,000 yuan per needle, and was implemented from January 1 this year, which greatly reduced the burden on the patient's family.
Spinal muscular atrophy is a rare disease of hereditary neuromuscular diseases, with an incidence of about 1/6000 to 1/10,000 in newborns in China, and there are currently more than 30,000 patients.
Reporter: Li Xiaobo
Produced by the Audio and Video Department of Xinhua News Agency